Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Hydroxychloroquine Sulfate Tablets from the Philippines Food and Drug Administration, allowing the product to be marketed [1] Group 1 - The product is manufactured by Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals [1] - The approval signifies a potential expansion of the company's market presence in the pharmaceutical sector [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received a drug registration certificate from the Philippines Food and Drug Administration for its Hydroxychloroquine Sulfate Tablets, allowing the company to sell the product in the Philippines, which is expected to positively impact its overseas market expansion [1] Group 1: Product Approval - The Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases exacerbated by sunlight [1] - The product was developed by Concordia Pharmaceuticals Inc and was first launched in the United States in 1955 [1] - Shanghai Pharmaceuticals' Hydroxychloroquine Sulfate Tablets were approved for domestic sale in China in December 1999 and passed the consistency evaluation for generic drugs in December 2021 [1] Group 2: Financial Aspects - The company has not incurred additional R&D expenses for the product's launch in the Philippines, with only registration-related costs amounting to approximately RMB 50,000 [1] - According to IQVIA data, the total sales revenue for Hydroxychloroquine Sulfate Tablets (200 mg) in the Philippines is projected to be USD 4.13 million in 2024 [1] Group 3: Market Impact - The approval signifies the company's qualification to sell the product in the Philippine market, which is expected to have a positive impact on the company's overseas market expansion and accumulate valuable experience [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, which are now approved for market launch [1] Group 1 - The approved drug, Hydroxychloroquine Sulfate Tablets, is primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases triggered or exacerbated by sunlight [1]

Group 1 - Shanghai Pharmaceuticals (601607) subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] - Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases triggered or exacerbated by sunlight [1]

Group 1 - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] - For the first half of 2025, Shanghai Pharmaceuticals' revenue composition is as follows: distribution accounts for 91.5%, industrial for 8.59%, retail for 2.97%, other businesses for 0.34%, and other for 0.08% [1] - As of the report date, Shanghai Pharmaceuticals has a market capitalization of 66.6 billion yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the company to market this product in the Philippines, which is expected to positively impact its overseas market expansion and provide valuable experience [1] Group 1 - The Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases exacerbated by sunlight [1] - The approval of the 200mg Hydroxychloroquine Sulfate Tablets signifies the company's qualification to sell this drug in the Philippine market [1] - This development is seen as a step forward for the company in expanding its international presence [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] Group 1 - The approved drug, Hydroxychloroquine Sulfate Tablets, is primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases exacerbated by sunlight [1]

Core Insights - HaiXi Pharmaceutical (02637.HK) was listed on the Hong Kong stock market on October 20, with a market capitalization of approximately HKD 8 billion [1] - The company is in the commercialization stage, with 15 generic drugs approved by the National Medical Products Administration and 4 innovative drugs in the research pipeline targeting oncology, ophthalmology, and respiratory diseases [1] - The revenue projections for HaiXi Pharmaceutical from 2022 to 2024 are HKD 213 million, HKD 317 million, and HKD 467 million, respectively, with net profits of HKD 69 million, HKD 118 million, and HKD 136 million [1] Company Overview - HaiXi Pharmaceutical has 15 commercialized generic drugs primarily used for treating digestive, cardiovascular, endocrine, neurological, and inflammatory diseases [1] - Among the 15 generic drugs, 4 are included in the national centralized procurement program [1] - The company has a research team of 112 personnel and a sales team of only 36 employees [1] Business Strategy - The company plans to continue supporting the development of innovative drugs through the sales of generic drugs [2] - Key operational strategies include increasing R&D investment, enhancing commercialization capabilities, improving R&D capacity, conducting GMP compliance checks, and focusing on talent recruitment and retention [2]